Navigation Links
Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research
Date:9/10/2008

Feldmann and Maini Honored for Discovery of New Class of Anti-Inflammatory

Drugs

BEERSE, Belgium, Sept. 10 /PRNewswire/ -- The 2008 recipients of The Dr. Paul Janssen Award for Biomedical Research, Professor Marc Feldmann, FMedSci, FAA, FRS and Emeritus Professor Sir Ravinder Maini, FRCP, FMedSci, FRS of the Kennedy Institute of Rheumatology, Imperial College London, are being honored during a scientific symposium today and at a formal award ceremony at the Dr. Paul Janssen Research Center in Beerse, Belgium tomorrow. Feldmann and Maini received the $100,000 prize for their role in the discovery of tumor necrosis factor-alpha (TNF-alpha) as an effective therapeutic target for rheumatoid arthritis and other chronic inflammatory conditions.

"Thanks to their pioneering biomedical research, Feldmann and Maini have significantly improved the lives of millions of patients with chronic inflammatory conditions," said Paul Stoffels, company group chairman, Global Research and Development, Pharmaceuticals, Johnson & Johnson. "We are delighted that the 2008 Dr. Paul Janssen Award is going to two researchers with a lifelong commitment to translational research. Their achievements would have been greatly appreciated by Dr. Paul Janssen, who himself was instrumental in the development of many important medicines."

For more than 20 years, Feldmann and Maini have collaborated on basic research and clinical trials that have transformed the treatment of people diagnosed with chronic inflammatory conditions. Feldmann and Maini investigated the role of cytokines, protein messenger molecules that drive inflammation, and found that a single cytokine, TNF-alpha, was responsible for the debilitating symptoms of inflammatory disease. In seeking ways to block TNF-alpha, they studied a monoclonal antibody previously developed for an unrelated condition. Clinical trials revealed rapid and dramatic improvement of rheumatoid disease a
'/>"/>

SOURCE Johnson & Johnson
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
2. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
3. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
4. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
5. Johnson & Johnson Announces Changes to Accelerate Growth
6. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
7. Two-time Defending NASCAR Sprint Cup Series Champion Jimmie Johnson Joins the Team at CORD:USE Cord Blood Bank to Help Win the Race for Life
8. MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care
9. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
10. Craig Johnson Joins Ardea Biosciences Board of Directors
11. Migenix averts proxy contest; reaches agreement with DJohnson holdings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Second generation biofuels are a viable solution ... However, as natural gas is very cheap, this is affecting ... as valuable as they could be in comparison to natural ... has made it difficult for renewable energy developers to get ... ground. For these reasons, certain companies have shifted their focused ...
(Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today a ... to provide access to Nanosyn,s microfluidics screening and ... for novel small molecule therapeutics. ... work with FORMA Therapeutics to explore key pathways ... FORMA Therapeutics, decision to work with us is ...
(Date:7/29/2014)... July 29, 2014  ImmunoClin Corporation (IMCL) is ... treatment of infectious diseases as well as nutraceuticals. ... prevention of pathologies like cardiovascular disease, Alzheimer,s disease ... ImmunoClin Corporation will complete the strategic relocation of ... , a key center of North American ...
(Date:7/29/2014)... Philadelphia’s newest entrepreneurial incubation space is ready ... The Innovation Center @3401 , a collaborative effort of ... Center to help attract and nurture start-up businesses in ... , The Innovation Center @3401 (ic@3401), which ... is the new home of DreamIt Ventures and ...
Breaking Biology Technology:Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3
... Support Fund,s Goal of Finding a Cure for ... Animal Health and the National,Thoroughbred Racing Association (NTRA) ... the NTRA Charities - Barbaro Memorial Fund. The,partnership,s ... across the horse,industry and encourage further support of ...
... Novinski to Discuss Plans for Company in 2008 ... 31 Emisphere,Technologies, Inc. (Nasdaq: EMIS ), ... Thursday, February 7, at 10:00 AM EST. President ... the company,s,emerging business strategy. Emisphere is a biopharmaceutical ...
... Board of Directors, SAN DIEGO, Jan. 31 ... therapeutics for the,treatment of Alzheimer,s disease, announced today ... A round of financing. The financing was led ... Partners. Additional,investors included AgeChem Venture Fund, and MC ...
Cached Biology Technology:Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund 2Emisphere to Host Business Strategy Conference Call on February 7 2Emisphere to Host Business Strategy Conference Call on February 7 3Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 2Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 3
(Date:7/29/2014)... has received from the National Institutes of Health ... project to support the further development of 23andMe,s ... , Specifically, the grant supports four areas ... to improve the company,s ability to identify novel ... to support the collection of a broader set ...
(Date:7/29/2014)... preterm babies latest research from the University of ... the brains of many preterm children can perform almost as ... by the University,s Robinson Research Institute has found ... injury in early life, their cognitive abilities as a teenager ... However, the results of the study, published in this month,s ...
(Date:7/29/2014)... disease it affects 1 in 100,000 people characterized ... While its cause remains unknown, a new study by a ... of Bonn in Germany and other European institutions confirms for ... study, published on 6 July in Nature Genetics , ... When we swallow, a sphincter in the lower esophagus opens, ...
Breaking Biology News(10 mins):23andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3Preterm children's brains can catch up years later 2Mysterious esophagus disease is autoimmune after all 2
... Yukon River Basin provide unique insights on climate change ... local communities. The USGS coordinated interviews with ... Mary,s and Pitka,s Point, Alaska, to document their observations ... such as unpredictable weather patterns and dangerous ice conditions, ...
... unlocked a mechanism behind the way short- and long-term motor ... research from a team led by Nicolas Schweighofer of ... could potentially pave the way to more effective rehabilitation for ... motor memory is actually the product of two processes: short-term ...
... Andrea Endimiani, M.D., Ph.D., Institute of Veterinary ... by the American Society for Microbiology (ASM) to ... combining basic microbiology, epidemiology, pharmacology, biochemistry, and molecular ... traits on the outcome of infections caused by ...
Cached Biology News:Observations of climate change from indigenous Alaskans 2Observations of climate change from indigenous Alaskans 3Motor memory: The long and short of it 2The American Society for Microbiology honors Andrea Endimiani 2The American Society for Microbiology honors Andrea Endimiani 3
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Anti-Cullin-1 Host: rabbit polyclonal Species Reactivity: human, mouse Applications: IHC(P), WB, IP Storage: 4C...
Request Info...
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
Biology Products: